Why Attend SITC 2024? SITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. ...
ITI Reports Positive Results from Its Phase 1 Clinical Trial in Patients Diagnosed with Merkel Cell Carcinoma
Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showed ...
Partnering With Patients: The Cornerstone of Cancer Care and Research May 31 - June 4, 2024 McCormick Place | Chicago, IL meetings.asco.org | #ASCO24
Join us at the World Vaccine Congress in Washington DC The Start-to-Finish of Vaccines - From research, immune profiling & clinical trials to manufacture and access. https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
BIO 2024 is heading back West to San Diego, CA at the San Diego Convention Center. We're looking forward to being back together in June! https://www.bio.org/events/bio-international-convention
Join us at AACR's Annual Meeting which is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share ...
Join us at the mRNA Process Development & Manufacturing Summit 2023 at the Boston Convention and Exhibit Center in Boston, MA, September 27-28. ITI Director of RNA Therapeutics Development, Prakash ...
“LAMP1 targeting of the large T antigen of Merkel cell polyomavirus” publication: Frontiers in Immunotherapy
Immunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in Frontiers ...
Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of ...
Immunomic Therapeutics' Prakash Koodathingal, Director of RNA Therapeutics Development, shares his insight into CQAs for saRNA for GEN magazine's "Expansion of the RNA Technology Universe." Read the full article here: ...
July 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how a ...
In the Washington Post article "How Jimmy Carter boosted a life-saving cancer drug," our scientific advisor Dr. Drew Pardoll provides his outlook on Carter's impact on immune therapy. Pardoll, the ...